Modified anti-CD3 therapy in psoriatic arthritis: A Phase I/II clinical trial

Journal of Rheumatology

Volumn 29, Issue 9, 2002, Pages 1907-1913

  Utset, Tammy O ^a   Auger, Julie A ^a   Peace, Donna ^a   Zivin, Robert A ^a   Xu, Danlin ^a   Jolliffe, Linda ^a   Alegre, Maria Luisa ^a   Bluestone, Jeffrey A ^a   Clark, Marcus R ^a  

^a MC 0930 ^*  (United States)

Author keywords

Clinical trial; Monoclonal antibody; OKT3; Psoriatic arthritis; Spondyloarthropathy

Indexed keywords

CYTOKINE; INTERLEUKIN 10; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY HUOKT3GAMMA1; OKT 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUROMONAB-CD3; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036733642     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
2. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
3. Immunosuppressive agents in organ transplantation: Past, present and future
4. OKT3 F(ab′)2 fragments - Retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release
5. General aspects of cytokine-release syndrome: Timing and incidence of symptoms
6. Monoclonal antibody therapy: Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression
7. Defective signal transduction via T-cell receptor-CD3 structure in T cells from rheumatoid arthritis patients
8. Decreased expression of signal-transducing CD3 ζ chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients
9. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo
10. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy
11. T cell inactivation and cytokine deviation promoted by anti CD3 mAbs
12. Humanized, nonmitogenic OKT3 antibody, huOKT3γ1(ala-ala): Initial clinical experience
13. Phase I trial of a humanized Fc receptor nonbinding OKT3 antibody, huOKT3γ1(ala-ala) in the treatment of acute renal allograft rejection
14. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA 1982-91
15. Psoriatic arthritis
16. HLA antigens in psoriatic arthritis
17. Predominance of CD8+ T lymphocytes in psoriatic arthritis
18. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis
19. The immunologic and genetic basis of psoriasis
20. Patterns of cytokine production in psoriatic synovium
21. Severe psoriasis - Oral therapy with a new retinoid
22. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of anti-CD3 antibodies
23. Humanized OKT3 antibodies: Successful transfer of immune modulating properties and idiotypic expression
24. Psoriatic arthritis: A quantitative overview of therapeutic options
25. Randomized, double-blinded, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis
26. Longterm methotrexate therapy in psoriatic arthritis: Clinical and radiological outcome
27. Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
28. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis
29. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
30. Natural history of psoriatic arthritis
31. Psoriatic arthritis - An analysis of 220 patients
32. Psoriatic arthritis: A clinical, immunological and radiological study of 180 patients
33. The stability and reversibility of Th1 and Th2 populations
34. Partial TCR signals delivered by FcR non-binding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets
35. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis
36. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
37. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis